Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares
Globe Newswire31-05-2024, 13:00
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26